Selpercatinib
- TRADE NAME: Retevmo (Loxo Oncology Inc)
- INDICATIONS:
Non-small cell lung cancer; thyroid cancer.
NOTE: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval my be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- CLASS: Kinase inhibitor, RET (Rearranged during Transfection) kinase inhibitor
- HALF-LIFE: 32 hours
FDA APPROVAL DATE: 05/08/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:acid-reducing agents (proton pump inhibitors, H2 receptor antagonists, locally-acting antacids), CYP2C8 and CYP3A substrates, CYP3A inducers, CYP3A inhibitors, Itraconazole, Midazolam, Omeprazole, Repaglinide, Rifampin
Can cause fetal harm. Advise females of reproductive potential of the possible risk to the fetus and to use effective contraception.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 02/10/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric